CHINA – Global Phama major Lupin announced that it has entered into a strategic partnership with Yabao Pharmaceutical Co. Inc to meet demand for quality drugs with pediatric formulations in the Chinese markets.
The demand for high quality pediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures.
The latest Chinese pediatric pharmaceutical market report indicated that the market for pediatric drugs in China is expected to reach 210 billion CNY (US$33 billion) in 2021, growing at a rate of 9.23%.
Dr. Fabrice Egros, president – corporate development and growth markets of Lupin said, “We are excited about this partnership as it paves the way for us to bring quality pediatric formulations to the growing needs of patients in China.”
In addition to marketing Lupin’s pediatric products in the Chinese market, it intends to expand its collaboration in other strategic therapeutics areas such as cardiometabolic, central nervous system and gastro-enterology.
Yabao Pharmaceuticals is a leading pharmaceutical company in China, with fully-fledged development, manufacturing, and commercialization in China.
This collaboration with Lupin suits its strategic development and innovation agenda besides complementing its well-established business in the modern traditional Chinese medicines and chemical generics.
In addition, this partnership has infused a fresh impetus into Yabao, which strives to develop its pediatric pipeline to address the urgent unmet needs in the market and to serve the pediatric patients.
Consequently, Yabao also looks forward to expanding the collaboration with Lupin in other areas.
Meanwhile, earlier on in January, Lupin entered into a partnership with Chinese-based pharmaceutical company, Foncoo Pharmaceuticals to provide high quality generic and complex generic medicines to patients.
At that time, Lupin stated that this partnership arrangement in China reinforces the company’s commitment to bringing high quality generic and complex medicines to patients across the world.
In other recent developments, Lupin has appointed Diana Amador-Toro as the Senior Vice President, Global compliance.
In this capacity, Diana will be responsible for leading Lupin’s Global Compliance function including training, internal audit, and investigations.
Diana brings in more than 38 years of field experience in US FDA’s Office of Regulatory Affairs (ORA).
She previously served in two leadership positions in ORA as the New Jersey District Director and as the Office of Pharmaceutical Quality Operations Division I Director.
In these roles, she provided executive leadership in directing and managing FDA pharmaceutical inspectional and compliance activities.
She has been recognized with numerous awards, including the U.S. FDA Commissioner’s Special Citation and FDA’s highest award, the Award of Merit.